White Paper
The Impact of Biosimilar Competition in Europe 2025
Jan 14, 2026
Download
The 11th edition of the ‘Impact of Biosimilar Competition in Europe’ report builds upon the perspectives from last year’s publication and provides a forward-looking view on the upcoming opportunities and challenges for biosimilar competition in Europe.Biosimilars continue to play a critical role in the European healthcare system by generating savings for payers, creating headroom for innovation, and expanding access to biologic therapy for patients. Since the first biosimilar was launched in 2006, biosimilar medicines have become a core component of an effective healthcare system. However, the biosimilar pipeline signals future headwinds, which have been highlighted in previous reports and remain relevant today.The report consists of novel observations on market conditions for 2025, and a streamlined set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. Previous observations remain relevant and have been refined or referenced to align with the report’s approach of sharing novel observations on the impact of biosimilar in the European healthcare system.
Contact Us